How combination regimens are restructuring late-line oncology trial design

Why combination is now the default in late-line

Late-line oncology indications are characterised by patients who have already cycled through one or more standard-of-care regimens. The eligible populations are smaller, the disease biology is more heterogeneous, and the bar for clinical benefit is variable. Single-agent trials in these settings have several structural challenges:

• Standard-of-care control arms in late-line are themselves often combinations (chemotherapy plus immunotherapy, doublet targeted therapies). Single-agent investigational arms compare against multi-agent control
• The size of the eligible population in many late-line settings is small enough that statistical power for single-agent superiority requires either substantial recruitment time or relatively large effect sizes
• The biology often supports rational combination logic (mechanism complementarity, resistance pattern coverage, immune-cold-tumour activation)

The regulatory framework has accommodated this through:

• More accepting of combination-as-investigational-arm designs in late-line settings
• Willingness to consider combination contributions where each component has a defensible biological rationale
• Use of biomarker-defined subpopulations to manage statistical power requirements within combination designs

What this means for trial design

Late-line oncology trial design now typically incorporates:

• Combination experimental arm with single-agent or combination control
• Biomarker-stratified randomisation
• Multiple primary endpoints (often progression-free survival and overall survival as co-primary)
• Translational endpoint integration to support combination contribution understanding

The patient-population definition has to be precise enough that the combination's logic is defensible. Broad late-line populations require very large effect sizes to detect combination benefit; precise biomarker-defined populations allow more efficient designs.

What this means for commercial planning

For sponsors with assets approaching late-line registration:

• Single-agent late-line registration is increasingly the residual approach. Combination-based registration is the default expectation
• The choice of combination partner is a strategic commercial decision, not just a clinical one. Partner asset selection affects label flexibility, reimbursement framing, and the eligible-population definition
• Real-world evidence on combination uptake patterns is now part of the post-launch evidence package, with implications for confirmatory commitments and managed-access agreements
• Indication-specific commercial framing is more granular when the registration is combination-based, with implications for medical-affairs and access-strategy resourcing

What we are watching

• Late-line registration pathways in indications where the combination convention is most established and how those frame next-generation registrations
• Translational combination data from biomarker-stratified trials that informs the next round of combination logic
• Adjacent oncology indications where combination-as-default is moving earlier in the line of therapy